Identification of potent Interleukin-1 Receptor-Associated Kinase 4 Inhibitors for treatment /prevention of septic shock: BIRAC – DBT Virtual Science & Technology Conference March 2021, New Delhi, India Lavleen Gupta, Y. Adinarayana Reddy, Deepali Srivastava, Dikshita
Rodent exercise model for evaluation of nutraceuticals and dietary supplements. ISSX 2021 International Conference, 14th to 17th July, 2021, Bangalore R. Pradeep, Rinku Kumar Das, Mahadeva Swamy & V.V. Vaidyanathan (2021) Vipragen Biosciences Pvt. Ltd.
Safety assessment of a standardized cucumber extract (Q-Actin™): Oral repeat-dose toxicity and mutagenicity studies Toxicology Reports 5 (2018) 1078–1086. S. Kotharia, M. Saravanan, S. Muthusamy, A. Mozingoc, M. Soni. Read more: https://pubmed.ncbi.nlm.nih.gov/30425929/
Identification of potent Interleukin-1 Receptor-Associated Kinase 4 Inhibitors for treatment /prevention of septic shock: BIRAC – DBT Virtual Science & Technology Conference March 2021, New Delhi, India
Lavleen Gupta, Y. Adinarayana Reddy, Deepali Srivastava, Dikshita Panwar, Dinesh Kumar, Manoj Sharma, Mona Gupta, M. R. Harsha, R. Pradeep, Rohit Kanekal, P. Shilpa, V.V. Vaidyanathan (2021) IgY Immunologix India Pvt Ltd & Vipragen Biosciences Pvt Ltd.
DBT/BIRAC Funding:
Project Title: Novel IRAK4 inhibitor for the treatment of septic shock Collaborators: IgY Immunologix India Pvt Ltd & Vipragen Biosciences Pvt. Ltd. Investigators: Principal Investigator: Lavleen Kumar Gupta, Ph.D. Co-investigator: V. V. Vaidyanathan, Ph.D. Proposal Number: BT/SBIRI1598/36/18
Rodent exercise model for evaluation of nutraceuticals and dietary supplements
ISSX 2021 International Conference, 14th to 17th July, 2021, Bangalore.
